MUNICH — Tubulis said it has appointed Charles Fuchs, M.D. as chief medical officer to lead the company’s clinical strategy and pipeline development as it advances its antibody-drug conjugate programs into later-stage clinical evaluation.
Fuchs, an internationally recognized oncology expert with more than three decades of experience, most recently served as senior vice president and global head of oncology and hematology product development at Roche and Genentech. He will provide strategic clinical and medical leadership as Tubulis moves its most advanced ADC candidates, TUB-040 and TUB-030, into later-stage trials and continues to expand its pipeline. He will be based in the company’s U.S. office in Cambridge, Mass.
“Tubulis is entering a critical phase with strong clinical momentum and a significant capital raise, making this the right time to add a leader of Charlie’s caliber to our team,” said Dominik Schumacher, Ph.D., chief executive officer and co-founder of Tubulis. “Over the course of his distinguished career, he has defined global oncology strategies, driven multiple drug approvals and led high-performing cancer centers. His strategic perspective and hands-on approach will be invaluable as we advance TUB-040 and TUB-030 and expand into additional indications. Charlie is joining a Tubulis team that has already demonstrated the ability to translate new ADC concepts into high-potential clinical candidates.”
“The TUB-040 data presented at ESMO underscore Tubulis’ emergence as a leader in ADC development, with the potential to reshape treatment for patients with solid tumors,” Fuchs said. “It is a great opportunity to join a company with a growing pipeline, a differentiated ADC platform and a clear commitment to turning cutting-edge science into meaningful patient benefit. I look forward to making a positive impact as Tubulis drives its programs through the clinic and builds a more mature pipeline.”
Fuchs has held leadership roles across academic medicine and the biopharmaceutical industry, contributing to advances in cancer biology, treatment, and prevention for more than 30 years. At Genentech and Roche, he led global oncology and hematology product development, overseeing portfolio growth and securing global regulatory approvals for multiple therapies, including Lunsumio, Columvi, Polivy, Crovalimab, Tecentriq, and Inavolisib, while also integrating external assets into the company’s pipeline.
Prior to joining industry, Fuchs served as cancer center director and physician-in-chief at Yale Cancer Center and Smilow Cancer Hospital, and earlier held senior roles at Dana-Farber Cancer Institute and Harvard Medical School, where he built leading research programs in gastrointestinal cancers and cancer epidemiology. He has also served in advisory and board roles at biotechnology and pharmaceutical companies, life science investment funds, and research organizations.
Fuchs has authored more than 700 peer-reviewed publications and is board certified in medical oncology. He holds an M.D. from Harvard Medical School and a Master of Public Health from the Harvard T.H. Chan School of Public Health.
